Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Monitoring of the effectiveness of drug therapy is one of the most debated issues in everyday clinical practice. The emergence of new drugs,  methods of analysis, standards, management protocols, and clinical guidelines increases the information load on practitioners and requires a significant investment of time and efforts for self-education. The purpose of the review is to help practitioners in summary form to obtain the necessary information on the issue of control of antiplatelet therapy. The review brings together data  from current  clinical recommendations on antiplatelet therapy in patients with ischemic heart disease, gives information of existing approaches to control of antiplatelet therapy specified in the guidelines and the consensuses of experts. It presents information on the most common modern methods of monitoring of the antiplatelet therapy effectiveness.

About the Authors

N. F. Puchinian
Saratov State Medical University named after V. I. Razumovsky
Russian Federation

Nikita F. Puchinian – MD, PhD, Researcher,  Department of Atherosclerosis and Chronic Ischemic Heart Disease, Research Institute of Cardiology.

Bolshaya Kazachia ul. 112, Saratov, 410012

N. V. Furman
Saratov State Medical University named after V. I. Razumovsky
Russian Federation

Nikolai V. Furman – MD, PhD, Head of Department of Emergency Cardiology, Research Institute of Cardiology.

Bolshaya Kazachia ul. 112, Saratov, 410012

L. I. Malinova
Saratov State Medical University named after V. I. Razumovsky
Russian Federation

Lidiya I. Malinova – MD, PhD, Head of Department of Atherosclerosis and Chronic Ischemic Heart Disease, Research Institute of Cardiology.

Bolshaya Kazachia ul. 112, Saratov, 410012

P. V. Dolotovskaya
Saratov State Medical University named after V. I. Razumovsky
Russian Federation

Polina V. Dolotovskaya – MD, PhD, Researcher,  Department of Emergency Cardiology, Research Institute of Cardiology.

Bolshaya Kazachia ul. 112, Saratov, 410012


1. Patrono C., Andreotti F., Arnesen H. et al Antiplatelet Agents for the Treatment and Prevention o8 f Atherothrombosis. Eur Heart J. 2011;32(23):2922-32.

2. Eikelboom J.W., Hirsh J., Spencer F.A., et al. Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e89S-e119S.

3. Sabouret P., Rushton-Smith S.K., Kerneis M. et al. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J Cardiovasc Pharmacother. 2015;1:198-204.

4. Zeymer U., Widimsky P., Danchin N. et al. P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):229-43.

5. De Luca L., Leonardi S., Smecca I. M. et al on behalf of the EYESHOT Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. Eur Heart J Cardiovasc Pharmacother. 2015;1:168-78.

6. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003.

7. The significance of platelet functional activity testing in the prevention of cardiovascular complications in patients receiving antiplatelet therapy. Conclusion of Interdisciplinary Expert Council of Russian Association of Angiologists and Vascular Surgeons, Russian Scientific Society of Endovascular Surgeons and Interventional Radiologists, National Stroke Association, National Scientific Inflammation Society. Rational Pharmacotherapy in Cardiology. 2014;10(6):679-87. (In Russ.) [Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. Заключение междисциплинарного Совета Экспертов Российского общества ангиологов и сосудистых хирургов, Российского научного общества специалистов по рентгенэндоваскулярной диагностике и лечению, Национальной ассоциации по борьбе с инсультами, Национального научного общества воспаления. Рациональная Фармакотерапия в Кардиологии. 2014;10(6):679-87].

8. Komarov A.L., Panchenko E.P. platelet function test for the assessment of thrombosis and bleeding risk in CHD patients taking antiplatelet medications. Rossiyskiy Kardiologicheskiy Zhurnal. 2015;(3):25-34. (In Russ.) [Комаров А.Л., Панченко Е.П. Тестирование функции тромбоцитов для оценки риска тромбозов и кровотечений у больных ИБС, получающих антиагреганты. Российский Кардиологический Журнал. 2015;3(119):25-34].

9. Grinshtein Yu.I., Kosinova A.A., Grinshtein I.Yu. Antiplatelet therapy control: credibility gap or search for new decisions? Rational Pharmacotherapy in Cardiology. 2013;9(6):682-9. Russian (Гринштейн Ю.И., Косинова А.А., Гринштейн И.Ю. Контроль антитромбоцитарной терапии: кризис доверия или поиск новых решений? Рациональная Фармакотерапия в Кардиологии. 2013;9(6):682-9].

10. Gum P.A., Kottke-Marchant K., Welsh al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-5.

11. Gurbel P.A., Becker R.C., Mann K.G. et al. Platelet Function Monitoring in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2007;50:1822-34.

12. Michelson A.D., Frelinger A.L., Furman M.I. Resistance to antiplatelet drugs. Eur Heart J. 2006;8:G53G58.

13. Aradi D., Kirtane A., Bonello L. et al. Bleeding and stent thrombosis on P2Y12 inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36:1762-71.

14. Tantry U.S., Bonello L., Aradi D. et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. J Am Coll Cardiol. 2013;62:2261-73.

15. Aradi D., Storey R.F., Komócsi A. et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209-15.

16. Sulimov V.A., Moroz E.V. Resistance to antiplatelet drugs (aspirin, clopidogrel) in patients undergoing elective percutaneous coronary intervention. Rational Pharmacotherapy in Cardiology. 2012;8(1):23-30. (In Russ.) [Сулимов В.А., Мороз Е.В. Резистентность к антитромбоцитарным препаратам (аспирину, клопидогрелу) у пациентов, подвергающихся элективному стентированию коронарных артерий. Рациональная Фармакотерапия в Кардиологии. 2012;8(1):23-30].

17. Kuliczkowski W., Witkowski A., Polonski L. et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009;30:426-35.

18. Bonello L., Tantry U.S., Marcucci R. et al. Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919-33.

19. Yavelov I.S. The role of determining the functional activity of platelets in the application in practice of clopidogrel treatment in patients with coronary heart disease. Aterotromboz. 2014;(1):22-32. (In Russ.) [Явелов И.С. Роль определения функциональной активности тромбоцитов при применении клопидогрела в практике лечения больных с коронарной болезнью сердца. Атеротромбоз. 2014;(1):22-32].

20. Michelson A.D., Cattaneo M., Eikelboom J.W. et al. Aspirin Resistance: position paper of the Working Group on Aspirin Resistance. on behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2005;3:1309-11.

21. Harrison P., Frelinger III A.L., Furman M.I., Michelson A.D. Measuring antiplatelet drug effects in the laboratory. Thrombosis Research. 2007;120:323-36.

22. Gratsiansky N.A. Antiplatelet Therapy in Coronary Heart Disease. Some Problems and Achivements. Kardiologiia. 2010;6:4-21. (In Russ.) [Грацианский Н.А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения. Кардиология. 2010;6:4-21].

23. Linnemann B., Schwonberg J, Mani H. et al. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost. 2008;6:677-83.

24. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430-5.

25. Ang L., Mahmud E. Monitoring Oral Antiplatelet Therapy: Is It Justified? Therapeutic Advances in Cardiovascular Disease. 2008;2(6):485-96.

26. Martin C.P., Talbert R.L. Aspirin Resistance: An Evaluation of Current Evidence and Measurement Methods. Pharmacotherapy. 2005;25(7):942-53.

27. Lordkipanidze M., Pharand C., Schampaert E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702-8.

28. Michelson A.D. Platelet Function Testing in Cardiovascular Diseases. Circulation. 2004;110:e489-e493.

29. Tantry U.S., Bliden K.P., Gurbel P.A. Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid Stimulation. J. Am Coll Cardiol. 2005;46:1705-9.

30. Aleil B., Meyer N., Cazenave J.P. et al. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost. 2005;94:886-7.

31. Bonello L., Camoin-Jau L., Arques S. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404-11.

32. Craft R.M., Chavez J.J., Snider C.C. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med. 2005;145:309-15.

33. Cattaneo M. Laboratory detection of ‘aspirin resistance’: what test should we use (if any)? Eur Heart J. 2007;28:1673-5.

34. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. Thromb Haemost. 2007;5(Suppl. 1):230-7.

35. Mason P.J., Jacobs A.K., Freedman J.E. Aspirin Resistance and Atherothrombotic Disease. J Am Coll Cardiol. 2005;46:986-93.

36. Gomez Y., Adams E., Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal. 2004;34(2):341-8.

37. Aradi D, Tornyos A., Pintér T. et al. Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing. Impact of Prasugrel and High-Dose Clopidogrel. J Am Coll Cardiol. 2014;63:1061-70.

For citation:

Puchinian N.F., Furman N.V., Malinova L.I., Dolotovskaya P.V. MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE. Rational Pharmacotherapy in Cardiology. 2017;13(1):107-115. (In Russ.)

Views: 487

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)